Chemogenomic discovery of allosteric antagonists at the GPRC6A receptor.

GPRC6A is a Family C G protein-coupled receptor recently discovered and deorphanized by our group. This study integrates chemogenomic ligand inference, homology modeling, compound synthesis, and pharmacological mechanism-of-action studies to disclose two noticeable results of methodological and pharmacological character: (1) chemogenomic lead identification through the first, to our knowledge, ligand inference between two different GPCR families, Families A and C; and (2) the discovery of the most selective GPRC6A allosteric antagonists discovered to date. The unprecedented inference of pharmacological activity across GPCR families provides proof-of-concept for in silico approaches against Family C targets based on Family A templates, greatly expanding the prospects of successful drug design and discovery. The antagonists were tested against a panel of seven Family A and C G protein-coupled receptors containing the chemogenomic binding sequence motif where some of the identified GPRC6A antagonists showed some activity. However, three compounds with at least ∼3-fold selectivity for GPRC6A were discovered, which present a significant step forward compared with the previously published GPRC6A antagonists, calindol and NPS 2143, which both display ∼30-fold selectivity for the calcium-sensing receptor compared to GPRC6A. The antagonists constitute novel research tools toward investigating the signaling mechanism of the GPRC6A receptor at the cellular level and serve as initial ligands for further optimization of potency and selectivity enabling future ex vivo/in vivo pharmacological studies.

Loss-of-function of IKAP/ELP1: could neuronal migration defect underlie familial dysautonomia?

Familial dysautonomia (FD) is a hereditary neuronal disease characterized by poor development and progressive degeneration of the sensory and autonomic nervous system. Majority of FD (99.5%) results from a single nucleotide point mutation in the IKBKAP gene encoding IKAP, also known as elongation protein 1 (ELP1). The point mutation leads to variable, tissue specific expression of a truncated IKBKAP mRNA. The appearance of the truncated IKBKAP coincides with a marked reduction of its wild type mRNA leading to decreased IKAP protein levels especially in the sensory and autonomous nervous system. Recently, two independent studies were carried out to establish a cellular model system to study the loss-of-function of IKAP in mammalian cells. Both studies used RNA interference to deplete wild type IKAP from different mammalian cell types. In both studies the depletion of IKAP resulted in a cell migration defect, revealing the importance of IKAP in this process. These studies lead to a common conclusion according to which defective neuronal migration could underlie FD. They gave however two very different explanations of how IKAP would regulate cell migration: via transcriptional regulation and via cytosolic interactions.